Relationship between Clostridioides difficile Infections and Antimicrobial Use in Patients with Hematopoietic Diseases
Abstract
Objective To clarify the impact of the continued use of broad-spectrum antibiotics on the cure and relapse rates of Clostridioides difficile infection (CDI) in patients with hematopoietic diseases. Methods In this retrospective cohort study, we evaluated 84 patients with hematopoietic disease who were diagnosed with CDI at Nippon Medical School Hospital between 2011 and 2023. Patients Patients with insufficient observation (<60 days) or no treatment were excluded from the study. Patients were categorized into sufficient (≥10 days, n=62) or insufficient (<10 days, n=22) treatment groups, and into continuation (n=37) or discontinuation (n=25) groups based on broad-spectrum antibiotic use following CDI onset. The primary endpoints were CDI cure and relapse, while the secondary endpoints were relapse risk factors. Kaplan-Meier curves with competing risks were used for comparison. Results The median age of the patients was 64 years. The underlying diseases included acute myeloid leukemia (35.7%), lymphoma (36.9%), and others. Cure rates, relapse rates, and relapse-free survival did not differ significantly between the sufficient and insufficient treatment groups (93.5% vs. 100%, p=0.569; 33.9% vs. 31.8%, p=1; 172 days vs. 257 days, p=0.783). The outcomes were also comparable between the continuation and discontinuation groups (89.1% vs. 100%, p=0.141; 27.0% vs. 44.0%, p=0.184; 215 days vs. 157 days, p=0.132), despite the higher neutropenia prevalence in the continuation group (51.4% vs. 24.0%, p=0.038). No independent predictors of relapse were identified in this study. Conclusion In patients with hematopoietic diseases, the continuation of broad-spectrum antibiotics did not adversely influence CDI cure or relapse rates. These findings suggest that continuing antibiotics is acceptable when clinically indicated for immunocompromised populations.
Related
- Clostridioides difficile infections and beyond: molecular epidemiology, One Health transmission chains, under-surveilled regions, and the next generation of diagnostics, therapeutics, and vaccines
- Epidemiology, risk factors and outcomes of Clostridioides difficile infection in a UK district general hospital: a retrospective cohort study
- Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains
- Effects of Antibiotic Use Reduction on Clostridioides difficile Colonization in Nursing Homes
BibTeX
@article{inai2026relationship,
title = {{Relationship between Clostridioides difficile Infections and Antimicrobial Use in Patients with Hematopoietic Diseases}},
author = {Kazuki Inai and Atsushi Marumo and Yohei Washio and Akihiro Shinoyama and Masahiro Sakaguchi and Shunsuke Yui and Satoshi Wakita and Hiroki Yamaguchi},
journal = {Internal Medicine},
year = {2026},
month = nov,
doi = {10.2169/internalmedicine.6567-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/21/65_6567-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Relationship between Clostridioides difficile Infections and Antimicrobial Use in Patients with Hematopoietic Diseases
AU - Kazuki Inai
AU - Atsushi Marumo
AU - Yohei Washio
AU - Akihiro Shinoyama
AU - Masahiro Sakaguchi
AU - Shunsuke Yui
AU - Satoshi Wakita
AU - Hiroki Yamaguchi
PY - 2026
DA - 2026/11/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6567-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/21/65_6567-25/_article
AB - Objective To clarify the impact of the continued use of broad-spectrum antibiotics on the cure and relapse rates of Clostridioides difficile infection (CDI) in patients with hematopoietic diseases. Methods In this retrospective cohort study, we evaluated 84 patients with hematopoietic disease who were diagnosed with CDI at Nippon Medical School Hospital between 2011 and 2023. Patients Patients with insufficient observation (<60 days) or no treatment were excluded from the study. Patients were categorized into sufficient (≥10 days, n=62) or insufficient (<10 days, n=22) treatment groups, and into continuation (n=37) or discontinuation (n=25) groups based on broad-spectrum antibiotic use following CDI onset. The primary endpoints were CDI cure and relapse, while the secondary endpoints were relapse risk factors. Kaplan-Meier curves with competing risks were used for comparison. Results The median age of the patients was 64 years. The underlying diseases included acute myeloid leukemia (35.7%), lymphoma (36.9%), and others. Cure rates, relapse rates, and relapse-free survival did not differ significantly between the sufficient and insufficient treatment groups (93.5% vs. 100%, p=0.569; 33.9% vs. 31.8%, p=1; 172 days vs. 257 days, p=0.783). The outcomes were also comparable between the continuation and discontinuation groups (89.1% vs. 100%, p=0.141; 27.0% vs. 44.0%, p=0.184; 215 days vs. 157 days, p=0.132), despite the higher neutropenia prevalence in the continuation group (51.4% vs. 24.0%, p=0.038). No independent predictors of relapse were identified in this study. Conclusion In patients with hematopoietic diseases, the continuation of broad-spectrum antibiotics did not adversely influence CDI cure or relapse rates. These findings suggest that continuing antibiotics is acceptable when clinically indicated for immunocompromised populations.
SN - 1349-7235
SN - 0918-2918
ER -